Resveratrol supplementation improves metabolic control in rats with induced hyperlipidemia and type 2 diabetes

Abstract

Resveratrol was recognized as the major factor responsible for the beneficial properties of red wine. Several resveratrol-based dietary supplements are available, but their efficacy has not been sufficiently tested. This study was designed to examine the effect of resveratrol supplementation, using a commercially available product, on the metabolic status of experimental animals with induced hyperlipidemia or type 2 diabetes mellitus (T2DM). Hyperlipidemia was induced by feeding the rats a standard pellet diet supplemented with cholesterol. T2DM was induced by adding 10% fructose to drinking water and streptozotocin. Treatment with resveratrol-based supplement improved glycemic control in diabetic animals and significantly decreased serum low-density-lipoprotein (LDL) and triglyceride levels, concurrently increasing the high-density-lipoprotein (HDL) levels in animals with hyperlipidemia. Resveratrol-treated animals had improved tolerance to glucose loading. Supplementation did not induce alterations in parameters of liver and renal function. Findings indicate that commercial resveratrol supplement improves metabolic control in rats with induced hyperlipidemia and T2DM.

Keywords: Diabetes; Hyperlipidemia; Metabolic parameters; Resveratrol.

Graphical abstract

Fig. 1

Overview of the treatment protocol.

Fig. 2

HPLC-DAD chromatogram of trans-resveratrol quantification in dietary supplement for calibration data: λ = 306 nm; calibration curve y = 32.2426x–0.207, x- peak area, y- concentration in mg/L; R² = 0.999; concentration range 2.5–40 mg/L. x- retention time (min), y- absorbance at 306 nm.

Fig. 3

Blood glucose levels (BGL) in rats with T2DM treated with saline (ConDiab) or dietary supplement based on resveratrol, 20 mg/kg (ResDiab). BGLbefore- prior to administration of streptozotocin, BGL0 − 48 h after the administration of streptozotocin and BGLend - on the last day of the experiment. *significantly different in comparison with ConDiab (p < 0.001).

Fig. 4

OGTT test results of rats with T2DM and rats fed high-cholesterol diet. ConS- control group, ConRes- rats treated with dietary supplement based on resveratrol (20 mg/kg), ConDiab- rats with diabetes, ResDiab- rats with diabetes treated with dietary supplement based on resveratrol (20 mg/kg), ConChol- rats with hiperlipidemia, ResChol- rats with hyperlipidemia treated with dietary supplement based on resveratrol, 20 mg/kg.